Back to top
more

Neuronetics (STIM)

(Real Time Quote from BATS)

$1.76 USD

1.76
92,071

-0.04 (-2.22%)

Updated Aug 5, 2024 02:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Integra (IART) Builds Advanced R&D Facility in New Jersey

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 2.56% and 2.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

5 Winning Medical Product Stocks That Still Have Room to Run

Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.

Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?

Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Neuronetics (STIM) Is Up 12.75% in One Week: What You Should Know

Does Neuronetics (STIM) have what it takes to be a top stock pick for momentum investors? Let's find out.

New Strong Buy Stocks for November 16th

ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 200% and 0.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

DexCom (DXCM) delivered earnings and revenue surprises of 16.67% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?

ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 0% and 7.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 20% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 0% and 6.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Community Health (CYH) Stock

With contract labor headwinds likely to phase out as 2022 progresses, Community Health Systems' (CYH) margins are set to improve significantly.